Jump to main content
Jump to site search

Issue 11, 2012
Previous Article Next Article

Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

Author affiliations

Abstract

An approach to characterize the interactions of RAPTA-T, a novel ruthenium-based anticancer drug candidate with intriguing antimetastatic properties, with human ovarian cancer cells in vitro is described. The distribution profile of the metallodrug within the cancer cells was determined by (size exclusion chromatography)-inductively coupled mass spectrometry combined with subcellular fractionation procedures (metallomics). Multidimensional protein identification technology (MudPIT) was then used to obtain insight into the alteration of the cellular proteome upon RAPTA-T treatment. The metallomics approach reveals striking differences in the intracellular behavior of the drug between cisplatin-sensitive and resistant cell lines and provides clues on possible mechanisms of action as well as detoxification, quantitative proteomics based on spectral counting sheds light on cellular response mechanisms to metallodrug treatment.

Graphical abstract: Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

Back to tab navigation

Publication details

The article was received on 18 Apr 2012, accepted on 21 Aug 2012 and first published on 22 Aug 2012


Article type: Paper
DOI: 10.1039/C2MT20070H
Metallomics, 2012,4, 1185-1196

  •   Request permissions

    Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

    D. A. Wolters, M. Stefanopoulou, P. J. Dyson and M. Groessl, Metallomics, 2012, 4, 1185
    DOI: 10.1039/C2MT20070H

Search articles by author

Spotlight

Advertisements